No abstract available Keywords: anaplastic thyroid cancer; follicular thyroid cancer; medullary thyroid cancer; papillary thyroid cancer; targeted therapy. Conflict of interest statement Disclosure CD has reported advisory boards for Eisai and Eli Lilly; DMH has received honoraria from Medtronic; SL has reported honoraria for advisory boards for Eisai, Lilly and Bayer and invited speaker for Eisai; LDL has reported advisory boards for MSD, Merck Serono and Eli Lilly and invited speaker for Eisai and consulting activity for Ipsen; KN has received honoraria as invited speaker from Eisai and nonremunerated advisory role for Ipsen; MGP has reported honoraria for advisory board for Eli Lilly and invited speaker for Roche; AB has received honoraria for advisory boards for Amgen, Astellas and Janssen, invited speaker for Amgen and institutional research funding from Astellas and Janssen; SF has declared no conflicts of interest.
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer / Filetti, S., Durante, C., Hartl, D.M., Leboulleux, S., Locati, L.D., Newbold, K., Papotti, M.G., Berruti, A.. - In: ANNALS OF ONCOLOGY. - ISSN 1569-8041. - 33:7(2022), pp. 674-684. [10.1016/j.annonc.2022.04.009]
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer
Filetti, S;Durante, C;
2022
Abstract
No abstract available Keywords: anaplastic thyroid cancer; follicular thyroid cancer; medullary thyroid cancer; papillary thyroid cancer; targeted therapy. Conflict of interest statement Disclosure CD has reported advisory boards for Eisai and Eli Lilly; DMH has received honoraria from Medtronic; SL has reported honoraria for advisory boards for Eisai, Lilly and Bayer and invited speaker for Eisai; LDL has reported advisory boards for MSD, Merck Serono and Eli Lilly and invited speaker for Eisai and consulting activity for Ipsen; KN has received honoraria as invited speaker from Eisai and nonremunerated advisory role for Ipsen; MGP has reported honoraria for advisory board for Eli Lilly and invited speaker for Roche; AB has received honoraria for advisory boards for Amgen, Astellas and Janssen, invited speaker for Amgen and institutional research funding from Astellas and Janssen; SF has declared no conflicts of interest.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
